TNGX - NASDAQ

Tango Therapeutics, Inc.

TNGX·NASDAQ

$22.04

+2.7%

HealthcareBiotechnology

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.56B

EPS-0.8700

P/E Ratio-25.34

Earnings Date08/04/2026

398.69M

Assets

26%

3Y-9.0%

5Y+92.0%

10Y+615.0%

52.51M

Total Liabilities

-55%

3Y-72.0%

5Y-69.0%

10Y+10.0%

346.18M

Total Equity

74%

3Y+39.0%

5Y+797.0%

10Y+4279.0%

Tango Therapeutics, Inc. Funding & Solvency Profile

TNGX · NASDAQ

Current Assets

Cash & Cash Equivalents112.28M

Net Receivables0.00

Inventory0.00

Other Current Assets10.62M

Total Current Assets354 M

Non-Current Assets

Property, Plant & Equipment42.49M

Goodwill & Intangible Assets0.00

Long-Term Investments0.00

Other Non-Current Assets2.44M

Total Non-Current Assets45 M

Total Assets

398.69M

Financial Health Analysis

Current Ratio

16.32x

Excellent liquidity position. The company can easily cover its short-term obligations with substantial cushion.

Debt-to-Equity Ratio

0.15x

Conservative capital structure. The company relies primarily on equity financing, indicating low financial risk.

Working Capital

332 M

Strong working capital position provides significant operational flexibility and financial cushion.

Asset Composition

89% Current

Asset-light business model with high liquidity. Majority of assets are easily convertible to cash.

Financial Health Insight

Strong financial foundation: Excellent liquidity combined with conservative leverage suggests the company is well-positioned to weather economic uncertainties and fund growth opportunities.

Tango Therapeutics, Inc. Balance Sheet

TNGX • NASDAQ

Tango Therapeutics, Inc. Balance Sheet	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
ASSETS
CURRENT ASSETS
Cash and Cash Equivalents	112.3M	69.5M	66.4M	60M	142.7M	28.4M	22.9M
Short-Term Investments	230.9M	188.4M	270.5M	306.2M	342.5M	161.9M	17.5M
Cash & Short-Term Investments	343.1M	257.9M	336.9M	366.1M	485.3M	190.3M	40.4M
Net Receivables	0.0	0.0	0.0	2M	2M	2M	0.0
Accounts Receivables	0.0	0.0	0.0	2M	2M	2M	0.0
Prepaids	0.0	0.0	0.0	0.0	4.5M	1.3M	1.2M
Other Current Assets	10.6M	8.4M	9.7M	7.1M	567K	0.0	0.0
Total Current Assets	353.8M	266.3M	346.5M	375.3M	492.3M	193.6M	41.7M
NON-CURRENT ASSETS
Property, Plant, and Equipment (Net)	42.5M	47.6M	53.4M	57.8M	6.1M	11.3M	11.8M
Other Non-Current Assets	2.4M	2.6M	2.6M	3.4M	1.7M	2.3M	2.3M
Total Non-Current Assets	44.9M	50.1M	56M	61.2M	7.8M	13.6M	14.1M
Total Assets	398.7M	316.5M	402.6M	436.5M	500.2M	207.3M	55.8M
LIABILITIES
CURRENT LIABILITIES
Total Payables	1.2M	1.6M	2.8M	4.5M	3.3M	1.8M	670K
Accounts Payable	1.2M	1.6M	2.8M	4.5M	3.2M	1.8M	670K
Other Payables	0.0	0.0	0.0	35K	52K	0.0	0.0
Accrued Expenses	0.0	14.8M	7.9M	16.2M	9.2M	5.3M	4.6M
Short Term Debt	2.7M	0.0	0.0	0.0	0.0	0.0	0.0
Capital Lease Obligations (Current)	0.0	2.5M	2.1M	1.8M	1.5M	959K	655K
Tax Payables	0.0	0.0	0.0	35K	52K	0.0	0.0
Deferred Revenue	0.0	17.6M	25.7M	31.8M	26M	32M	0.0
Other Current Liabilities	17.8M	1.7M	7.5M	1.3M	666K	793K	19.9M
Total Current Liabilities	21.7M	38.2M	45.9M	55.5M	40.7M	40.9M	25.9M
NON-CURRENT LIABILITIES
Long Term Debt	30.8M	0.0	0.0	0.0	0.0	0.0	0.0
Deferred Revenue (Non-Current)	0.0	44.8M	66.7M	92.1M	114.7M	120.8M	0.0
Other Non-Current Liabilities	0.0	0.0	0.0	0.0	0.0	5K	14.1M
Total Non-Current Liabilities	30.8M	78.8M	103.5M	131.4M	114.7M	127.7M	22M
Capital Lease Obligations	0.0	36.5M	38.9M	41.1M	1.5M	7.9M	8.5M
Total Liabilities	52.5M	117M	149.5M	187M	155.4M	168.7M	47.9M
SHAREHOLDERS' EQUITY
Preferred Stock	0.0	0.0	0.0	0.0	0.0	0.0	55.7M
Common Stock	136K	108K	102K	88K	88K	40K	13K
Additional Paid-In Capital	949M	700.6M	624.1M	522.6M	506.8M	141.6M	3.3M
Retained Earnings	-603.2M	-501.6M	-371.3M	-269.5M	-161.3M	-103.1M	-51.1M
Accumulated Other Comprehensive Income/Loss	224K	336K	186K	-3.7M	-765K	17K	10K
Total Stockholders' Equity	346.2M	199.5M	253.1M	249.5M	344.7M	38.6M	7.9M
Total Equity	346.2M	199.5M	253.1M	249.5M	344.7M	38.6M	7.9M
SUMMARY
Total Liabilities & Equity	398.7M	316.5M	402.6M	436.5M	500.2M	207.3M	55.8M
Total Investments	230.9M	188.4M	270.5M	306.2M	342.5M	161.9M	17.5M
Total Debt	33.6M	36.5M	38.9M	41.1M	1.5M	7.9M	8.5M
Net Debt	-78.7M	-33M	-27.5M	-18.8M	-141.2M	-20.5M	-14.4M
Shares Outstanding	110,466,777	110,466,777	110,466,777	110,466,777	110,466,777	110,466,777	110,466,777

SEC Filings

TNGX - Filing history and reports

Filing Type	Filing Date	Period Ending	Fiscal Year	Actions
8-K 8-K 2026 N/A	May 13, 2026	May 13, 2026	2026	View Filing
10-Q 10-Q 2026 Q1 Q1	May 13, 2026	March 31, 2026	2026	View Filing
8-K 8-K 2026 N/A	May 08, 2026	May 07, 2026	2026	View Filing
DEF 14A DEF 14A 2026 N/A	April 17, 2026	April 16, 2026	2026	View Filing
8-K 8-K 2026 N/A	April 15, 2026	April 10, 2026	2026	View Filing
8-K 8-K 2026 N/A	March 05, 2026	March 05, 2026	2026	View Filing
10-K 10-K 2025 FY FY	March 05, 2026	December 31, 2025	2025	View Filing
8-K 8-K 2026 N/A	January 08, 2026	January 07, 2026	2026	View Filing
8-K 8-K 2026 N/A	January 05, 2026	January 02, 2026	2026	View Filing
S-3 S-3 N/A	November 21, 2025	November 21, 2025		View Filing

Showing 1 to 10 of 81 filings

Related Guides

Blog Categories

Continue your TNGX research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.